Curadigm, a Nanobiotix SA subsidiary, is an early-stage nanotechnology company dedicated to improving outcomes for patients by shifting the therapeutic delivery paradigm.

Curadigm’s Nanoprimer technology is designed to increase drug bioavailability while decreasing unintended off-target effects, specifically liver toxicity. The technology can be used with most intravenous (IV) therapeutics across multiple drug classes.

Curadigm is dedicated to advancing therapeutic development based on our deep understanding of how drugs interact with the body, to impact both known and novel drugs across multiple clinical indications.


Visit our website